Aridis Pharmaceuticals Announces Its AR-301 Program Has Been Deemed Eligible For Consideration Under FDA Limited Population Pathway For Antibacterial And Antifungal Drugs
Portfolio Pulse from Benzinga Newsdesk
Aridis Pharmaceuticals announced that its AR-301 program has been deemed eligible for consideration under the FDA Limited Population Pathway for Antibacterial and Antifungal Drugs.
June 20, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aridis Pharmaceuticals' AR-301 program has been deemed eligible for consideration under the FDA Limited Population Pathway, potentially accelerating its approval process.
The FDA Limited Population Pathway eligibility for Aridis Pharmaceuticals' AR-301 program is a positive development for the company. This pathway is designed to expedite the development and approval of antibacterial and antifungal drugs, which could potentially accelerate the approval process for AR-301. As a result, this news is likely to have a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100